Conference symposium
Real-World AI for HFpEF & Amyloidosis: Unlocking Diagnostic Power from a Single Echo View
Featuring expert insights from Mayo Clinic, The University of Chicago Medicine, and City of Hope, this session presents real-world case studies, customer implementation examples, and results from the 2025 landmark trial of the first FDA-cleared AI echo-based screening tool for Cardiac Amyloidosis.
Patricia A. Pellikka M.D
Jeremy A. Slivnick, MD
Faizi A. Jamal, MD, FACC
